The European Medicine Agency (EMA) has started a rolling review of the COVID-19 vaccine developed by Chinese company Sinovac, the latest vaccine candidate hoping to win approval for usage in the bloc.

In a press statement on 4th May, the EMA announced that the application for the vaccine was submitted by Italy-based Life'On S.r.l., Xinhua reported. "The vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease", said the EMA. The Chinese vaccine uses an inactivated form of the SARS-CoV-2, which cannot cause the disease. Once inoculated, the vaccinated person will start producing antibodies against the virus, hence becoming ready to fight the virus should contact be made later on, according to the EMA.

Sinovac will be evaluated with the usual European Union (EU) standards for effectiveness, safety and quality, said the agency. So far, four vaccines developed by BioNTech/Pfizer, Moderna, AstraZeneca and Johnson & Johnson, have been granted conditional marketing authorization. Four other vaccines are under rolling review, including Sinovac, CureVac, Novavax and Sputnik V. A rolling review is a regulatory tool that the EMA uses to speed up the assessment of a promising medicine during a public health emergency. No EU country currently uses the Sinovac vaccine. However, EU-member Hungary has decided to vaccinate its population using the Sinopharm COVID-19 vaccine, another Chinese vaccine.